@entity16850 is the most common benign neoplasm of the larynx. Juvenile onset @entity16850 tends to recur. In @entity1 with adult onset @entity16850 , @entity5 rarely develops. This paper reports a clinical analysis of 60 @entity1 with @entity16850 who were treated at our clinic between January 1971 and September 2009. We analyzed the sex ratio, age at the onset of @entity1185 , type of developing @entity1185 (single or multiple type), site of developing @entity1185 , recurrence rate, and therapeutic modalities. Furthermore, the clinical characteristics of the @entity1 with @entity5 were examined. The @entity1 were classified according to their age at the onset of the @entity1185 and the type of developing @entity1185 . The @entity1 were grouped into a juvenile-onset group and an adult-onset group according to their age at the onset of the @entity1185 . They were also classified into single-type or multiple-type according to whether the initial @entity1185 appeared singly or multiply. The male to female sex ratios were 1.2 in the juvenile-onset group and 5.1 in the adult-onset group. Among the @entity1 who developed @entity1185 at an age of under 10 years old, most of the juvenile cases had experienced onset by 4 years of age. Furthermore, the frequency of @entity1185 was significantly higher in the juvenile-onset group, compared with the adult-onset group. The vocal fold was the most frequent site of the @entity1185 . The recurrence rate in the juvenile-onset group was significantly higher than that of the adult-onset group. A stratified analysis according to the type of @entity1185 occurrence, however, showed no significant difference in recurrences between the juvenile-onset and adult-onset groups. A stratified analysis according to the age at the onset of @entity1185 showed that the recurrence rate of @entity1185 was significantly higher than that of single-type @entity1185 in the adult-onset group. Among multiple therapeutic modalities, vaporization by @entity544 laser was the most frequently used. Adjuvant therapy was performed in 6 cases who suffered from multiple relapses. The injection of interferon was performed in 5 cases, and the local injection of @entity7076 was performed in 1 case. @entity5 was confirmed in 3 cases. The periods between the onset of @entity1185 and the @entity5 were 40 years, 14 years, and 3 years. The present study indicates that @entity1 with @entity1724 developing at multiple sites have a significantly higher rate of relapse, even in the adult-onset group. There was no tendency in the period observed between the onset of @entity1185 and @entity5 . From the standpoint of recurrence and @entity5 , @entity1 with @entity1185 should be carefully followed up for a long period of time.

[ XXXX : A Statistical Analysis of 60 Cases].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity16850 :: ('MESH:C537876', 'Disease') :: ['Laryngeal papillomatosis', 'laryngeal papillomatosis'] @entity1724 :: ('MESH:C535297', 'Disease') :: ['laryngeal papilloma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['laryngeal cancer', 'Malignant transformation of the papilloma', 'malignant transformation'] @entity1185 :: ('MESH:D010212', 'Disease') :: ['papillomatosis', 'multiple-type papilloma', 'papilloma'] @entity544 :: ('MESH:D002245', 'Chemical') :: ['carbon dioxide'] @entity7076 :: ('MESH:C059262', 'Chemical') :: ['cidofovir']
@entity16850 :: (MESH:C537876,Disease) :: ['Laryngeal Papillomatosis']
